Ensysce Biosciences Inc (ENSC) Stock Price, Quote & News

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4196

Website: www.ensysce.com

Address:

7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

Sunnybhargava Jul. 15 at 3:41 AM

$ENSC interesting it says since it’s NIDA funded program so they try to pull interim out before quarter end like end of July. Hopefully the grant and interim results have to do something with each other.

0 · Reply

Sunnybhargava Jul. 15 at 3:39 AM

$ENSC

0 · Reply

Sunnybhargava Jul. 15 at 2:39 AM

$ENSC

0 · Reply

ricdidkou Jul. 14 at 11:55 PM

$ENSC ELPW may do it

0 · Reply

shahidattar Jul. 14 at 11:46 PM

$ENSC They still can RS if they don't gain compliance. Today's absorption of warrants or convertibles help them in the shareholders equity rule but does not help with the minimum price rule. They still can RS with a ratio of 1:16 or below.

1 · Reply

Usually_Im_Right Jul. 14 at 11:34 PM

$ENSC buy zone

0 · Reply

Mateine Jul. 14 at 10:05 PM

$ENSC That S‑3 filing allows resale of up to 20.3 M shares from existing preferred and warrant conversions; it doesn’t mean those shares were released today. The volume we saw likely reflects liquidity absorption or position rebalancing after the NIDA grant news. If anyone spots a Form 4 or 8‑K confirming actual conversions or warrant exercises, please share; that would clarify whether any of those registered shares entered the market.

1 · Reply

Mikelnite80 Jul. 14 at 9:57 PM

$ENSC yall saw it was running why TF would u sell it????

0 · Reply

Sunnybhargava Jul. 14 at 9:34 PM

$ENSC heavy trading after hours

0 · Reply

stockinvestbull Jul. 14 at 9:30 PM

$ENSC curling 👀

0 · Reply

Ensysce Biosciences awarded $5.3M installment in NIDA funding

Jul 14, 2026, 8:00 AM EDT - 1 day ago

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

2026-06-26T12:05:15.000Z - 19 days ago

Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102

Jun 26, 2026, 8:00 AM EDT - 19 days ago

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

2026-06-04T20:45:12.000Z - 5 weeks ago

Ensysce Biosciences files to sell 1.3M shares of common stock for holders

Jun 4, 2026, 8:00 AM EDT - 5 weeks ago

Ensysce Biosciences Registration statement: Registration filing

May 15, 2026, 4:15 PM EDT - 2 months ago

Ensysce Biosciences Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 2 months ago

Ensysce Biosciences Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

Ensysce Biosciences Earnings release: Q1 2026

2026-05-12T15:40:41.000Z - 2 months ago

Ensysce announces expansion of patent protection for MPAR technology

May 12, 2026, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

May 8, 2026, 8:00 AM EDT - 2 months ago

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Apr 20, 2026, 7:00 AM EDT - 3 months ago

Ensysce Biosciences Slides: Investor presentation

2026-04-16T13:08:30.000Z - 3 months ago

Ensysce secures IRB approval of final phase of PF614-MPAR-102 study

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Apr 9, 2026, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Registration statement: Registration filing

2026-04-09T10:12:51.000Z - 3 months ago

Ensysce Biosciences files to sell 20.34M shares of common stock for holders

2026-04-07T12:52:56.000Z - 3 months ago

Ensysce Biosciences secures second financing from 2025 agreement

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Mar 30, 2026, 4:50 PM EDT - 3 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 30, 2026, 4:00 PM EDT - 3 months ago

Ensysce Biosciences Annual report: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 3 months ago

Ensysce Biosciences Earnings release: Q4 2025

2026-03-04T13:51:12.000Z - 4 months ago

Ensysce Biosciences announces initiation of ‘Ask Me Anything’ series

Mar 4, 2026, 8:45 AM EST - 4 months ago

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

2026-03-03T13:32:48.000Z - 4 months ago

Ensysce Biosciences announces publication on MPAR technology

Mar 3, 2026, 8:00 AM EST - 4 months ago

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

2026-02-25T13:17:50.000Z - 4 months ago

Ensysce Biosciences initiates review of strategic alternatives

Feb 25, 2026, 8:00 AM EST - 4 months ago

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Feb 23, 2026, 8:00 AM EST - 5 months ago

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

2026-01-28T13:26:39.000Z - 5 months ago

Ensysce Biosciences enrolls 50% of subjects in Phase 3 trial of PF614

Jan 28, 2026, 8:00 AM EST - 5 months ago

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

2026-01-21T13:15:40.000Z - 6 months ago

Ensysce Biosciences expands global opioid patent portfolio

Jan 21, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio

2026-01-08T13:52:10.000Z - 6 months ago

Ensysce Biosciences receives EU patent for ADHD therapy

Jan 8, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 7, 2026, 12:00 PM EST - 6 months ago

Ensysce Biosciences Transcript: AGM 2025

2026-01-05T14:30:53.000Z - 6 months ago

Ensysce Biosciences CEO says ‘positioned for continued momentum’

Jan 5, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Dec 16, 2025, 7:00 AM EST - 7 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

Dec 12, 2025, 8:00 AM EST - 7 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

2025-12-09T13:25:51.000Z - 7 months ago

Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614

Dec 9, 2025, 8:00 AM EST - 7 months ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

2025-12-02T22:00:54.000Z - 8 months ago

Ensysce Biosciences files to sell 4.6M shares of common stock for holders

2025-12-02T13:35:42.000Z - 8 months ago

Ensysce Biosciences issued notice of allowance for MPAR tech patent

Dec 2, 2025, 8:00 AM EST - 8 months ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Dec 2, 2025, 7:00 AM EST - 8 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

Dec 2, 2025, 7:00 AM EST - 8 months ago

Ensysce Biosciences Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 8 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

2025-11-20T13:36:22.000Z - 8 months ago

Ensysce Biosciences receives FDA feedback on PF614 manufacturing

Nov 20, 2025, 8:00 AM EST - 8 months ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

2025-11-17T13:30:26.000Z - 8 months ago

Ensysce Biosciences secures $4M financing

Nov 17, 2025, 8:05 AM EST - 8 months ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 14, 2025, 4:15 PM EST - 8 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:00 PM EST - 8 months ago

Ensysce Biosciences Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 8 months ago

Ensysce Biosciences Quarterly report: Q3 2025

2025-10-10T12:20:20.000Z - 9 months ago

Ensysce Biosciences releases symposium highlights from PAINWeek 2025

Oct 10, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Aug 19, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Ensysce Biosciences Slides: Investor Presentation

Aug 13, 2025, 4:15 PM EDT - 11 months ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Ensysce Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Ensysce Biosciences Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 13, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

May 2, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 4:41 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 10, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Ensysce Biosciences Annual report: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q4 2024

Mar 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 9:43 AM EST - 1 year ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 10, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 4, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 3, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Nov 26, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 19, 2024, 7:00 AM EST - 1 year ago

Ensysce Biosciences Proxy statement: Proxy Filing

Nov 12, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Sunnybhargava Jul. 15 at 3:41 AM

0 · Reply

Sunnybhargava Jul. 15 at 3:39 AM

$ENSC

0 · Reply

Sunnybhargava Jul. 15 at 2:39 AM

$ENSC

0 · Reply

ricdidkou Jul. 14 at 11:55 PM

$ENSC ELPW may do it

0 · Reply

shahidattar Jul. 14 at 11:46 PM

1 · Reply

Usually_Im_Right Jul. 14 at 11:34 PM

$ENSC buy zone

0 · Reply

Mateine Jul. 14 at 10:05 PM

1 · Reply

Mikelnite80 Jul. 14 at 9:57 PM

$ENSC yall saw it was running why TF would u sell it????

0 · Reply

Sunnybhargava Jul. 14 at 9:34 PM

$ENSC heavy trading after hours

0 · Reply

stockinvestbull Jul. 14 at 9:30 PM

$ENSC curling 👀

0 · Reply

StockDreamin Jul. 14 at 9:21 PM

$ENSC same old crap with all these bios...I smell bullshit! R/S will be soon!

0 · Reply

Sunnybhargava Jul. 14 at 9:14 PM

$ENSC may be phase 3 interim or partnership or buyout coming sooner then we think ? Just my observation. Do your research and let us know if you find something

0 · Reply

Sunnybhargava Jul. 14 at 9:12 PM

$ENSC they filed this s3 for 20 million warrants shares. I know they file before phase 3 interim so when big pump they can sell those shares so did they release those today?

0 · Reply

Sunnybhargava Jul. 14 at 9:09 PM

$ENSC what was that volume. Did they release millions of warrants share which they filed in s3? And incentive shares? For interim. Someone load those shares , and there were not in dark pool finra. So what were those shares? Before market.

0 · Reply

ka1954 Jul. 14 at 8:10 PM

$ENSC back to .25 or less tomorrow, then again back to .30. they are keeping this pinned here

0 · Reply

Mateine Jul. 14 at 8:09 PM

$ENSC I completely understand the frustration; today’s news was objectively great, yet the price barely moved. In microcaps, strong fundamentals often take time to translate into price action because liquidity is being absorbed and positions are rebalanced. The $5.3M NIDA grant is real, non‑dilutive and milestone‑based ; that’s a major validation. If anyone finds additional filings or insider updates, please share; the more facts we gather, the better we can understand what’s happening behind this 18.8M+ volume.

0 · Reply

StockDreamin Jul. 14 at 7:49 PM

$ENSC wow! It went up a penny!

0 · Reply

Sunnybhargava Jul. 14 at 7:19 PM

$ENSC it’s not Lynn money. It’s our money she have. 😄

0 · Reply

BULLISH1975 Jul. 14 at 7:01 PM

$ENSC at some point in 2026 the big money will go from shorts to longs imo!!!! follow the money! this Science has the potential to be worth 100s of millions.

0 · Reply

BULLISH1975 Jul. 14 at 6:59 PM

$ENSC imagine if Lynn actually bought shares with her own money!!!!!!

0 · Reply

Sunnybhargava Jul. 14 at 6:33 PM

$ENSC please do something to improve the value of this stock. Since now you get funds more then the market cap. Also update shareholders about phase 3 interim .Thank you

0 · Reply

Sunnybhargava Jul. 14 at 5:14 PM

$ENSC

0 · Reply

Market Cap	4.23M
Revenue (ttm)	5.07M
Net Income (ttm)	-10.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-200.79%
Debt to Equity Ratio	0.00

Volume	19,717,699
Avg Vol	3,109,846
Day's Range	N/A - N/A
Shares Out	15.37M
Stochastic %K	74%
Beta	0.78
Analysts	Strong Buy
Price Target	$16.45